Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.

Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, and Pantone®, the global authority on color and provider of professional color standards for the design industries, today announced the creation of Omnipod Mango, a bright and joyful tropical orange yellow. Omnipod Mango was uniquely selected to celebrate the radiance of the diabetes community and symbolizes Insule.

Insulet and Pantone® Partner to Launch Omnipod® Mango in Vibrant New Palette

Medical device maker Insulet said on Tuesday that it appointed industry veteran Flavia Pease as its new chief financial officer and expects to exceed its previously issued third-quarter total revenue growth outlook.

Medical device maker Insulet names industry veteran Flavia Pease as CFO

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. “I want to personally thank Ana, who has provided steady and thoughtful leader.

Insulet Announces CFO Transition

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Insulet (PODD) is a Strong Momentum Stock

Insulet Corporation (NASDAQ:PODD ) Baird Global Healthcare Conference 2025 September 9, 2025 12:15 PM EDT Company Participants Eric Benjamin - Executive VP & COO Ana Chadwick - Executive VP & CFO Conference Call Participants Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Presentation Jeffrey Johnson Senior Research Analyst Jeff Johnson.

Insulet Corporation (PODD) Presents At Baird Global Healthcare Conference 2025 Transcript

Insulet Corporation (NASDAQ:PODD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 3:00 PM EDT Company Participants Ashley McEvoy - CEO, President & Director Ana Chadwick - Executive VP & CFO Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Welcome back.

Insulet Corporation (PODD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Here's Why Insulet (PODD) is a Strong Growth Stock

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Eric Benjamin to Chief Operating Officer effective immediately. The Company also announced the appointment of Manoj Raghunandanan as Chief Growth Officer. In this expanded role, Mr. Benjamin will lead Insulet's end-to-end growth and innovation engine, setting strategy and guiding.

Insulet Elevates Eric Benjamin to Chief Operating Officer

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.

Insulet Gains 77.2% in a Year: What's Driving the Rally?

The Omnipod maker reported 113% earnings growth, sending shares higher.

Omnipod Maker Hit A Buy Point. Here's Where To Pick Up Shares.

The Investment Committee give you their top stocks to watch for the second half.

Final Trades: Rocket Companies, Cisco Systems, Insulet Corp and the IGV

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the upcoming investor conferences (all Eastern Time): Wells Fargo 2025 Healthcare Conference in Boston on September 4 at 3:00 p.m. Baird 2025 Global Healthcare Conference in New York City on September 9 at 12:15 p.m. Bernstein Insights: Healthcare Leaders & Disruptors Forum in New York Ci.

Insulet to Participate in Upcoming Investor Conferences

PODD delivered strong Q2 results, exceeding revenue guidance, improving gross margin, and launching the Omnipod 5 iPhone app, strengthening its ecosystem position. Omnipod 5's pharmacy channel penetration and positive clinical data support sustained >20% annual revenue growth and margin expansion over the next 3-5 years. The market underestimates the long-term impact of pharmacy distribution, which reduces onboarding friction, broadens payer access, and improves retention economics.

Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold

PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.

Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise

Real-time stock quote and overview for PODD